Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.

Anderson GR, Wardell SE, Cakir M, Yip C, Ahn YR, Ali M, Yllanes AP, Chao CA, McDonnell DP, Wood KC.

Nat Commun. 2018 Apr 26;9(1):1677. doi: 10.1038/s41467-018-04033-x.

2.

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

Tria GS, Abrams T, Baird J, Burks HE, Firestone B, Gaither LA, Hamann LG, He G, Kirby CA, Kim S, Lombardo F, Macchi KJ, McDonnell DP, Mishina Y, Norris JD, Nunez J, Springer C, Sun Y, Thomsen NM, Wang C, Wang J, Yu B, Tiong-Yip CL, Peukert S.

J Med Chem. 2018 Apr 12;61(7):2837-2864. doi: 10.1021/acs.jmedchem.7b01682. Epub 2018 Mar 22.

PMID:
29562737
3.

Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery.

McDonnell DP, Norris JD, Chang CY.

Cancer Cell. 2018 Feb 12;33(2):153-155. doi: 10.1016/j.ccell.2018.01.014.

PMID:
29438688
4.

Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.

McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP.

Prostate. 2018 Mar;78(4):266-277. doi: 10.1002/pros.23467. Epub 2017 Dec 15.

PMID:
29243324
5.

The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.

Baek AE, Yu YA, He S, Wardell SE, Chang CY, Kwon S, Pillai RV, McDowell HB, Thompson JW, Dubois LG, Sullivan PM, Kemper JK, Gunn MD, McDonnell DP, Nelson ER.

Nat Commun. 2017 Oct 11;8(1):864. doi: 10.1038/s41467-017-00910-z.

6.

DNA Sequence Constraints Define Functionally Active Steroid Nuclear Receptor Binding Sites in Chromatin.

Coons LA, Hewitt SC, Burkholder AB, McDonnell DP, Korach KS.

Endocrinology. 2017 Oct 1;158(10):3212-3234. doi: 10.1210/en.2017-00468.

PMID:
28977594
7.

A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.

Liberti MV, Dai Z, Wardell SE, Baccile JA, Liu X, Gao X, Baldi R, Mehrmohamadi M, Johnson MO, Madhukar NS, Shestov AA, Chio IIC, Elemento O, Rathmell JC, Schroeder FC, McDonnell DP, Locasale JW.

Cell Metab. 2017 Oct 3;26(4):648-659.e8. doi: 10.1016/j.cmet.2017.08.017. Epub 2017 Sep 14.

PMID:
28918937
8.

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.

Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT.

Oncogene. 2017 Jul 27;36(30):4379. doi: 10.1038/onc.2017.192. Epub 2017 Jun 12.

PMID:
28604749
9.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

10.

Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.

Kimbung S, Chang CY, Bendahl PO, Dubois L, Thompson JW, McDonnell DP, Borgquist S.

Endocr Relat Cancer. 2017 Jul;24(7):339-349. doi: 10.1530/ERC-16-0533. Epub 2017 Apr 25.

11.

Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.

Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.

J Med Chem. 2017 Apr 13;60(7):2790-2818. doi: 10.1021/acs.jmedchem.6b01468. Epub 2017 Mar 15.

PMID:
28296398
12.

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.

Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ, Kishton RJ, Lawrence SA, Strum JC, McDonnell DP.

Mol Cancer Res. 2017 Jun;15(6):660-669. doi: 10.1158/1541-7786.MCR-17-0028. Epub 2017 Feb 16.

13.

MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.

Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK.

Horm Cancer. 2017 Apr;8(2):69-77. doi: 10.1007/s12672-017-0285-6. Epub 2017 Feb 13.

14.

CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.

Alfaqih MA, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, Geradts J, Thompson JW, Dubois LG, Freeman MR, Chang CY, Chi JT, McDonnell DP, Freedland SJ.

Cancer Res. 2017 Apr 1;77(7):1662-1673. doi: 10.1158/0008-5472.CAN-16-2738. Epub 2017 Jan 27.

15.

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC.

Sci Transl Med. 2016 Dec 14;8(369):369ra175.

16.

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.

Alexander PB, Chen R, Gong C, Yuan L, Jasper JS, Ding Y, Markowitz GJ, Yang P, Xu X, McDonnell DP, Song E, Wang XF.

J Biol Chem. 2017 Jan 13;292(2):748-759. doi: 10.1074/jbc.M116.754960. Epub 2016 Nov 30.

17.

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.

Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT.

Oncogene. 2017 Jul 27;36(30):4235-4242. doi: 10.1038/onc.2016.394. Epub 2016 Nov 21. Erratum in: Oncogene. 2017 Jun 12;:.

18.

Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.

Nelson ER, Li S, Kennedy M, Payne S, Kilibarda K, Groth J, Bowie M, Parilla-Castellar E, de Ridder G, Marcom PK, Lyes M, Peterson BL, Cook M, Pizzo SV, McDonnell DP, Bachelder RE.

Oncotarget. 2016 Dec 20;7(51):84030-84042. doi: 10.18632/oncotarget.12767.

19.

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.

Pollock JA, Wardell SE, Parent AA, Stagg DB, Ellison SJ, Alley HM, Chao CA, Lawrence SA, Stice JP, Spasojevic I, Baker JG, Kim SH, McDonnell DP, Katzenellenbogen JA, Norris JD.

Nat Chem Biol. 2016 Oct;12(10):795-801. doi: 10.1038/nchembio.2131. Epub 2016 Aug 8.

20.

ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.

Park S, Chang CY, Safi R, Liu X, Baldi R, Jasper JS, Anderson GR, Liu T, Rathmell JC, Dewhirst MW, Wood KC, Locasale JW, McDonnell DP.

Cell Rep. 2016 Apr 12;15(2):323-35. doi: 10.1016/j.celrep.2016.03.026. Epub 2016 Mar 31.

21.

MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.

Xu X, Zhang Y, Jasper J, Lykken E, Alexander PB, Markowitz GJ, McDonnell DP, Li QJ, Wang XF.

Oncotarget. 2016 Apr 12;7(15):20381-94. doi: 10.18632/oncotarget.7953.

22.

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.

Jones ME, Andrews JS, Faries DE, Landry J, Xu J, Detke HC, Chhabra-Khanna R, McDonnell DP.

BMC Psychiatry. 2015 Nov 13;15:278. doi: 10.1186/s12888-015-0669-5.

23.

Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus.

Blessing AM, Ganesan S, Rajapakshe K, Ying Sung Y, Reddy Bollu L, Shi Y, Cheung E, Coarfa C, Chang JT, McDonnell DP, Frigo DE.

Mol Endocrinol. 2015 Oct;29(10):1426-39. doi: 10.1210/me.2015-1079. Epub 2015 Aug 25.

24.

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.

Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP.

Endocr Relat Cancer. 2015 Oct;22(5):713-24. doi: 10.1530/ERC-15-0287. Epub 2015 Jul 10.

25.

Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.

Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, Tae HS, Sundberg TB, Stagg DB, Hines J, McDonnell DP, Norris JD, Crews CM.

Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9659-62. doi: 10.1002/anie.201503720. Epub 2015 Jun 17.

26.

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation.

Anand E, Berggren L, Deix C, Tóth Á, McDonnell DP.

Neuropsychiatr Dis Treat. 2015 May 27;11:1349-57. doi: 10.2147/NDT.S79347. eCollection 2015.

27.

Pregnancy and Smoothelin-like Protein 1 (SMTNL1) Deletion Promote the Switching of Skeletal Muscle to a Glycolytic Phenotype in Human and Mice.

Lontay B, Bodoor K, Sipos A, Weitzel DH, Loiselle D, Safi R, Zheng D, Devente J, Hickner RC, McDonnell DP, Ribar T, Haystead TA.

J Biol Chem. 2015 Jul 17;290(29):17985-98. doi: 10.1074/jbc.M115.658120. Epub 2015 Jun 5.

28.

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.

McDonnell DP, Wardell SE, Norris JD.

J Med Chem. 2015 Jun 25;58(12):4883-7. doi: 10.1021/acs.jmedchem.5b00760. Epub 2015 Jun 3.

29.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S.

Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.

30.

Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR.

Mol Oncol. 2015 Jun;9(6):1155-68. doi: 10.1016/j.molonc.2015.02.007. Epub 2015 Feb 21.

31.

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.

32.

Cholesterol and breast cancer pathophysiology.

Nelson ER, Chang CY, McDonnell DP.

Trends Endocrinol Metab. 2014 Dec;25(12):649-55. doi: 10.1016/j.tem.2014.10.001. Epub 2014 Nov 4. Review.

33.

Copper signaling axis as a target for prostate cancer therapeutics.

Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, McDonnell DP.

Cancer Res. 2014 Oct 15;74(20):5819-31. doi: 10.1158/0008-5472.CAN-13-3527.

34.

The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer.

McDonnell DP, Chang CY, Nelson ER.

Climacteric. 2014 Dec;17 Suppl 2:60-5. doi: 10.3109/13697137.2014.966949. Epub 2014 Oct 16.

35.

Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways.

Choudhary M, Kazmin D, Hu P, Thomas RS, McDonnell DP, Malek G.

J Pathol. 2015 Jan;235(1):101-12. doi: 10.1002/path.4433. Epub 2014 Oct 10.

36.

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.

Mol Cancer Res. 2014 Dec;12(12):1829-39. doi: 10.1158/1541-7786.MCR-14-0195. Epub 2014 Aug 6.

37.

From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).

Wardell SE, Nelson ER, McDonnell DP.

Steroids. 2014 Nov;90:30-8. doi: 10.1016/j.steroids.2014.07.013. Epub 2014 Jul 30.

38.

Obesity, cholesterol metabolism, and breast cancer pathogenesis.

McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY, Norris JD, Guyton JR, Nelson ER.

Cancer Res. 2014 Sep 15;74(18):4976-82. doi: 10.1158/0008-5472.CAN-14-1756. Epub 2014 Jul 24.

39.

Use of phage display to identify novel mineralocorticoid receptor-interacting proteins.

Yang J, Fuller PJ, Morgan J, Shibata H, McDonnell DP, Clyne CD, Young MJ.

Mol Endocrinol. 2014 Sep;28(9):1571-84. doi: 10.1210/me.2014-1101. Epub 2014 Jul 7.

40.

Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.

Detke HC, Lauriello J, Landry J, McDonnell DP.

Int J Methods Psychiatr Res. 2014 Dec;23(4):439-50. doi: 10.1002/mpr.1443. Epub 2014 Jul 3.

41.
42.

Pregnancy without progesterone in horses defines a second endogenous biopotent progesterone receptor agonist, 5α-dihydroprogesterone.

Scholtz EL, Krishnan S, Ball BA, Corbin CJ, Moeller BC, Stanley SD, McDowell KJ, Hughes AL, McDonnell DP, Conley AJ.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3365-70. doi: 10.1073/pnas.1318163111. Epub 2014 Feb 18.

43.

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.

Atkins S, Detke HC, McDonnell DP, Case MG, Wang S.

BMC Psychiatry. 2014 Jan 14;14:7. doi: 10.1186/1471-244X-14-7.

44.

Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis.

Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC.

Psychiatry Clin Neurosci. 2014 Jul;68(7):498-505. doi: 10.1111/pcn.12156. Epub 2014 Mar 4.

45.

4,4'-Unsymmetrically substituted 3,3'-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors.

Weiser PT, Chang CY, McDonnell DP, Hanson RN.

Bioorg Med Chem. 2014 Jan 15;22(2):917-26. doi: 10.1016/j.bmc.2013.10.051. Epub 2013 Nov 8.

46.

27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP.

Science. 2013 Nov 29;342(6162):1094-8. doi: 10.1126/science.1241908.

47.

Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology.

Hu P, Herrmann R, Bednar A, Saloupis P, Dwyer MA, Yang P, Qi X, Thomas RS, Jaffe GJ, Boulton ME, McDonnell DP, Malek G.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):E4069-78. doi: 10.1073/pnas.1307574110. Epub 2013 Oct 8.

48.

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.

Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC.

BMC Psychiatry. 2013 May 14;13:138. doi: 10.1186/1471-244X-13-138.

49.

Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

Wardell SE, Nelson ER, Chao CA, McDonnell DP.

Clin Cancer Res. 2013 May 1;19(9):2420-31. doi: 10.1158/1078-0432.CCR-12-3771. Epub 2013 Mar 27.

50.

ELF3 is a repressor of androgen receptor action in prostate cancer cells.

Shatnawi A, Norris JD, Chaveroux C, Jasper JS, Sherk AB, McDonnell DP, Giguère V.

Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.

Supplemental Content

Loading ...
Support Center